Zecuity Patent Expiration

Zecuity is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is protected by 10 US drug patents filed from 2013 to 2016. Out of these, 9 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 08, 2032. Details of Zecuity's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9327114 User-activated self-contained co-packaged iontophoretic drug delivery system
Oct, 2032

(7 years from now)

Active
US8983594 Electronic control of drug delivery system
Nov, 2030

(6 years from now)

Active
US8366600 Polyamine enhanced formulations for triptan compound iontophoresis
Apr, 2029

(4 years from now)

Active
US9272137 Transdermal methods and systems for the delivery of anti-migraine compounds
Sep, 2027

(2 years from now)

Active
US8470853 Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(2 years from now)

Active
US8155737 Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(2 years from now)

Active
US9427578 Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(2 years from now)

Active
US7973058 Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(2 years from now)

Active
US8597272 Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(2 years from now)

Active
US6745071 Iontophoretic drug delivery system
Feb, 2023

(1 year, 7 months ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zecuity's patents.

Given below is the list of recent legal activities going on the following patents of Zecuity.

Activity Date Patent Number
Patent litigations
Expire Patent 10 Jun, 2024 US9327114
Maintenance Fee Reminder Mailed 25 Dec, 2023 US9327114
Expire Patent 24 Apr, 2023 US8983594
Maintenance Fee Reminder Mailed 07 Nov, 2022 US8983594
Expire Patent 10 Jan, 2022 US8597272
Expire Patent 02 Aug, 2021 US8470853
Maintenance Fee Reminder Mailed 26 Jul, 2021 US8597272
Maintenance Fee Reminder Mailed 15 Feb, 2021 US8470853
Expire Patent 05 Oct, 2020 US9427578
Payment of Maintenance Fee, 8th Year, Large Entity 28 Jul, 2020 US8366600


FDA has granted several exclusivities to Zecuity. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zecuity, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zecuity.

Exclusivity Information

Zecuity holds 1 exclusivities. All of its exclusivities have expired in 2016. Details of Zecuity's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jan 17, 2016

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Zecuity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zecuity's family patents as well as insights into ongoing legal events on those patents.

Zecuity's Family Patents

Zecuity has patent protection in a total of 14 countries. It's US patent count contributes only to 24.2% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Zecuity.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Zecuity's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 08, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zecuity Generics:

Sumatriptan Succinate is the generic name for the brand Zecuity. 29 different companies have already filed for the generic of Zecuity, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zecuity's generic

Alternative Brands for Zecuity

Zecuity which is used for treating acute migraines in adults., has several other brand drugs using the same active ingredient (Sumatriptan Succinate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Currax
Onzetra Xsail
Treximet
Endo Operations
Sumavel Dosepro
Meridian Medcl
Alsuma
Tonix Meds
Zembrace Symtouch


Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan Succinate, Zecuity's active ingredient. Check the complete list of approved generic manufacturers for Zecuity





About Zecuity

Zecuity is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is used for treating acute migraines in adults. Zecuity uses Sumatriptan Succinate as an active ingredient. Zecuity was launched by Teva Branded Pharm in 2013.

Approval Date:

Zecuity was approved by FDA for market use on 17 January, 2013.

Active Ingredient:

Zecuity uses Sumatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Sumatriptan Succinate ingredient

Treatment:

Zecuity is used for treating acute migraines in adults.

Dosage:

Zecuity is available in system form for iontophoresis use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 6.5MG BASE/4HR SYSTEM Discontinued IONTOPHORESIS